{
    "title": "RL32324",
    "content": "Public interest in lower cost prescription drugs, especially for the elderly, has sparked debate on the government's role in supporting pharmaceutical development. Some argue that government funding of health-related R&D should result in lower drug prices, while others believe in letting the market drive innovation and pricing. Government involvement in research is seen as crucial for technological advancement and economic growth, as returns from basic research benefit society as a whole. Government funding of fundamental research is essential as the benefits accrue to society as a whole. To ensure that research results are applied to generate new goods and services, Congress has passed legislation to facilitate technology commercialization. Policies include incentives for private sector investment in technology development through technology transfer and intellectual property rights. The goal is to encourage academia and industry to utilize federally supported R&D to meet market demand. The current legislative approach aims to balance public needs for new technologies with concerns over accountability and compensation for companies. Government reserves rights for federal intervention in health and safety issues as safeguards. Critics argue that incentives for research are less necessary due to free access to federally funded results, patent protection, and regulatory advantages. Some experts argue that government incentives for pharmaceutical and biotechnology industries have been crucial for innovation and competitiveness. They compare it to government support for other industries like telecommunications and aviation. The paper explores government funding for research and development to support private sector commercialization, without addressing drug pricing issues. The report examines how the NIH supports research for new pharmaceuticals through collaboration among academia, industry, and government. It discusses government funding for R&D to meet mission requirements and promote technological progress. The U.S. government is expected to spend $138.9 billion in FY2012 on research and development. Government funding for basic research is essential as it is not typically performed in the private sector. The social rate of return on R&D spending is often much higher than the benefits captured by individual firms, leading to underinvestment by businesses. Incentives for private sector financial commitments are limited due to the high risk of failure and long-term, non-marketable rewards of basic research. Congressional initiatives have expanded the government's role in promoting technological innovation to meet national needs, particularly economic growth. Technological advancement is crucial for economic growth, with experts attributing up to half of the U.S. economy's growth to technical progress. Industrial expansion now relies more on scientific discoveries and engineering knowledge, leading to the creation of new goods, services, industries, jobs, and capital. Technology also helps in resolving national problems and expanding the range and distribution of services. Technological progress is achieved through innovation, with research and development playing a crucial role in economic growth by impacting productivity. Investments in R&D have been found to directly contribute to productivity growth in industries and firms. Innovations arising from R&D have led to significant changes in society, particularly in areas such as medicine, semiconductors, computers, and materials. Government policies and practices incentivize private sector utilization of research and development results to create new products and processes in various industries. Legislative initiatives promote collaboration between government, industry, and academia to commercialize government-funded research, fostering innovation and economic growth. Cooperative ventures facilitate the exchange of ideas and expertise, leading to increased creativity and invention in R&D. Industry has a growing interest in cooperative efforts with government and academia to combine ideas, expertise, and know-how for more creativity and invention. The rising costs of research and development, driven by new technologies and shortened product cycles, have led to increased company support for technology development. Partnerships in R&D are necessary due to intense competition, information overload, and the need for new approaches beyond individual funding. Cooperative R&D allows for expensive or marginally valuable work to be done collectively, enabling companies to acquire new technologies while maintaining control. External alliances in R&D allow companies to access innovations without high costs or risks. Collaboration helps firms acquire necessary research from outside sources, leading to increased productivity growth. A survey by PriceWaterhouseCoopers showed that businesses outsourcing R&D are growing faster and more profitable. In 2007, U.S. companies contracted out 7.8% of their R&D expenditures, reflecting a growing trend in external R&D support. Joint ventures, however, may not always be successful due to various factors. Less than 2% of industry funding was directed at extramural research, with joint ventures facing challenges such as failed concepts, cultural differences, and conflicting goals. However, studies show benefits of partnering including increased sales, improved competitive position, and higher growth rates. Fast-growing U.S. firms have seen success through partnerships, leading to more innovative products and profit opportunities. Collaborative growth firms prioritize new product development and innovation, with 81% of U.S. manufacturing survey respondents engaging in some form of collaboration. The pharmaceutical industry has seen a significant increase in strategic alliances, particularly between large businesses and small biotech companies. Ernst & Young reported a doubling of alliances from 2005 to 2006, with strong growth in 2007 and 2008. In 2010, U.S. strategic alliances between pharmaceutical firms and biotech companies continued to rise for the third consecutive year, leading to a 119.2% increase in R&D expenditures contracted out between 2000 and 2005. Research shows that these alliances have positive effects on R&D performance. Research indicates that alliances in the pharmaceutical industry between 2000 and 2005 have led to a third of new products being developed through collaborations, with higher success rates in clinical trials. Wheaton College Professor Kejun Song suggests that concentrating talents through co-development alliances can speed up innovation commercialization. Merging technological knowledge from different companies improves the innovation process, while industry-university cooperation in R&D also facilitates technological advancements. Advancement in academia is funded by the government, with companies increasingly relying on this community for knowledge to develop commercial products. Over 90% of life science companies in the US had partnerships with universities by the mid to late 1990s. Academic faculty with industry relationships were found to be more productive. Academic departments and pharmaceutical companies have established relationships, with studies showing that new products and processes rely on recent academic research. Recent academic research has played a crucial role in the development of new FDA-approved drugs and vaccines. Between 9.3 and 21.2% of new drug applications approved from 1990 to 2007 were a result of work done in public-sector research institutions. Additionally, 31% of scientifically novel drugs approved by the FDA between 1998 and 2007 originated from research conducted in universities. This collaborative work, whether between government-industry, government-university, industry-university, or industry-industry, is supported by the patent system to promote innovation and the progress of science and the useful arts. The patent system, grounded in the Constitution, aims to stimulate innovation by granting exclusive rights to inventors for 20 years. This encourages investment in developing new technologies while also placing the concept in the public domain. The patent system grants inventors exclusive rights for 20 years to stimulate innovation. This disclosure system encourages parallel technical developments and does not deplete the stock of knowledge, making innovation a public good. The patent system grants inventors exclusive rights for 20 years to stimulate innovation by creating incentives that maximize the difference between the value of intellectual property and the social cost of its creation. Patents allow for control over novel concepts or discoveries, resolving the problem of appropriability and ensuring a return on investments for inventors. Research is crucial for innovation, constituting approximately 25% of the cost of commercializing new technologies, requiring substantial resources to bring products to the marketplace. The grant of a patent provides inventors with exclusive rights for 20 years to capture returns on their inventions, encouraging further development and marketable technology. Patents are crucial in drug and chemical industries due to detailed claims, but in other sectors, inventing around patents and disclosure of information limit their protection. In industries like aircraft and semiconductors, lead time and learning curve strength are more important for capturing investment benefits. In industries like aircraft and semiconductors, lead time and learning curve strength are more important for capturing investment benefits. The patent system aims to provide incentives for inventors to invent and disclose technical information, leading to competitiveness and technological progress. The patent system is seen as crucial for technological progress, but it has faced criticism. Some argue that market forces alone can drive innovation, while others believe patents lead to industry concentration and hinder market entry. The lack of rigorous analytical methods makes it challenging to assess the impact of patent law on the economy. The lack of rigorous analytical methods makes it challenging to assess the impact of patent law on the economy. Legislative provisions use intellectual property rights to foster collaboration in research and development for new products and processes. The Bayh-Dole Act and the Stevenson-Wydler Act aim to promote collaboration in R&D and technology transfer, impacting interactions between government agencies, academia, and industry. These laws address intellectual property issues arising from federal government-funded technologies, with a focus on encouraging innovation while balancing drug cost containment. The Stevenson-Wydler Act promotes technology transfer from federal laboratories to outside organizations, encouraging the use of technologies developed in the federal laboratory system. It establishes mechanisms for transferring technology and creating cooperative research and development agreements. The Federal Technology Transfer Act of 1986 and the FY1990 Department of Defense Authorizations created cooperative research and development agreements (CRADAs) for technology transfer. CRADAs are legal documents that define collaborative ventures at the laboratory level, allowing for the exchange of funds, personnel, services, and property between parties. The government can cover overhead costs but cannot provide direct funding to the industrial partner. Patents derived from collaborative work are subject to agency policies, with the non-federal party having the option for an exclusive license. The Federal Technology Transfer Act of 1986 and the FY1990 Department of Defense Authorizations established cooperative research and development agreements (CRADAs) for technology transfer. CRADAs allow for collaborative ventures at the laboratory level, with the non-federal party having the option for an exclusive license for inventions. The government retains certain rights, including the ability to require licensing to address health and safety needs or if obligations are not met by the cooperating party. CRADAs are cooperative agreements that promote technology transfer, with preference given to small businesses and companies manufacturing in the US. These agreements allow for collaborative ventures, including personnel exchanges, patent licensing, and educational initiatives. Federal laboratories are restricted from competing with the private sector and can only offer expertise and equipment not readily available elsewhere. The Bayh-Dole Act, P.L. 96-517, was created to promote the utilization of inventions made with federal research support by allowing universities, nonprofit institutions, and small businesses to own certain patents. This was necessary as only 5% of federally owned patents were being used, partly due to agencies taking title to all inventions made with government funding. The Act aimed to encourage companies to engage in additional R&D and bring ideas to the marketplace by providing ownership of patents. The Bayh-Dole Act incentivizes cooperative work and commercial application by granting ownership of patents to universities, nonprofit institutions, and small businesses for inventions arising from federally funded R&D. Royalties from intellectual property rights support further research in the academic community and provide a return on investment for the business sector. Nonprofit organizations and small businesses can elect to retain title to \"subject inventions\" under certain conditions. The Bayh-Dole Act allows universities, nonprofit institutions, and small businesses to own patents for inventions from federally funded R&D. The government can withhold title under certain circumstances, such as national security concerns or if the contractor is foreign-controlled. The government retains a license to practice any subject invention worldwide. The Bayh-Dole Act allows universities, nonprofit institutions, and small businesses to own patents for inventions from federally funded R&D. The government retains a nonexclusive license to practice any subject invention worldwide and has \"march-in rights\" to require licensing in certain circumstances. Section 209 of the Bayh-Dole Act outlines the licensing regulations for inventions from federally funded R&D. Federal departments can offer nonexclusive, exclusive, or partially exclusive licenses with specific conditions. The government retains rights to terminate the license if commercialization is not pursued as outlined in the business plan or for public use. Notices about patent availability for licensing must be published in the Federal Register for three months. Small businesses are given preferences for licenses, and licensees must agree to manufacture products substantially in the United States. The primary mission of the National Institutes of Health is to advance scientific knowledge for healthier lives. The National Institutes of Health (NIH) funds over $30.9 billion for research and development, with the majority going to contractors like universities and research institutions. The agency is mandated to transfer new technologies to the private sector for commercialization. NIH aims to promote health through bioscience research and support the domestic biotechnology industry. Specific issues in health research have raised concerns not seen in other sectors. Issues in health research have raised concerns not seen in other sectors, leading to questions about the adequacy of current arrangements. Closer cooperation between public and private sectors can increase funding sources, technology transfer, innovation, and market expansion. However, collaboration may also lead to unfair advantages, conflicts of interest, and less openness in sharing scientific discoveries. NIH conducts intramural research, keeping title to inventions made in its laboratories and filing numerous patent applications annually. In FY2012, NIH disclosed 352 inventions, filed 147 patent applications, and issued 130 patents. $111.2 million in royalties were collected on existing licenses, compared to $51.0 million in FY2002. Over the FY2002-FY2012 period, $917.7 million in royalties were generated. NIH identified 26 FDA approved products developed with NIH intramural research technology. NIH was responsible for 95% of royalties collected by six agencies studied between 1996 and 1998. The Department of Health and Human Services (HHS), including the National Institutes of Health (NIH), had the largest number of licensing agreements and generated the most income from technologies licensed by federal laboratories. The Public Health Service (PHS) and other agencies aim to transfer new technologies to the private sector efficiently while balancing market competition. Cooperative Research and Development Agreements (CRADAs) at NIH must align with the agency's mission requirements. NIH's Cooperative Research and Development Agreements (CRADAs) must align with the agency's mission requirements and not divert resources. Scientific input from collaborators should enhance government scientists' capabilities. Publication of research results is required, with a focus on technology transfer and scientific freedom. NIH patents inventions from intramural R&D and prefers licensing over assigning patent titles to outside entities. The organization prefers licensing over assigning patent titles to outside entities for biomedical technologies to facilitate public access. Under a CRADA, the producing party retains ownership of inventions, data, and materials, with joint ownership for collaborative work. Collaborators may have the option for an exclusive license to inventions not solely made by their employees, reflecting contributions, development plans, risks, and costs. The CRADA involves the development and marketing of the CRADA Subject Invention, with decisions on licensing made to ensure broad applications. Non-exclusive or co-exclusive licenses are preferred, with mandatory exclusive licenses requiring sublicenses for public health. Technologies must be made available for research purposes and commercialized promptly, with royalty-bearing licenses for a fair return on the public's research investment. The NIH aims to ensure fair pricing and a reasonable relationship between public investment in research and the pricing of products licensed under CRADAs. This policy was established by the Public Health Service in 1989 to guarantee a fair financial return on the public's research investment. The NIH established a policy in 1989 to ensure fair pricing and a reasonable relationship between public investment in research and product pricing under CRADAs. The pricing clause, instituted in response to concerns over the cost of AZT, was removed in 1995 at the request of the NIH Director after public hearings revealed it hindered scientific collaborations without benefiting the public. The fair pricing clause in NIH CRADAs caused concerns among companies and hindered collaborations. Industry sources felt uncertainty about pricing deterred them from entering into cooperative arrangements. Many pharmaceutical and biotechnology firms declined CRADAs due to the pricing clause, leading to calls for its repeal by patient advocacy groups. NIH was hesitant to make definitive decisions on pricing. The fair pricing clause in NIH CRADAs was a point of contention, with patient advocacy groups calling for its repeal. NIH was hesitant to make pricing decisions, with Dr. Healy suggesting a more hands-off approach. After the clause was rescinded in April 1995, the number of CRADAs executed by NIH increased significantly. Since the repeal of the fair pricing clause in April 1995, the number of CRADAs executed by NIH has increased substantially. Extramural research, mainly at universities or medical centers, makes up the majority of NIH research funding. The Bayh-Dole Act mandates that federal departments and agencies do not retain title to inventions made with government funding when research is done by an outside contractor. This has led to successful commercialization of technology, with a significant increase in patents awarded to universities. In 1980, 390 patents were awarded to universities, increasing to 3,088 by 2009. Federal government funding supports 51.7% of R&D expenditures in the medical and biological sciences at academic institutions. Academic research, largely funded by the government, is crucial for business growth, with companies tied to universities showing higher productivity rates. Over one-quarter of new drugs in the pharmaceutical industry rely on academic research for commercialization. Public-sector research institutions are expected to have a significant therapeutic impact. Research institutions, including universities, are noted to have a disproportionately large therapeutic effect. NIH funded basic research contributes significantly to pharmaceutical product innovation. Public science, supported by governmental, academic, and charitable institutions, plays a crucial role in private sector technology development. Recent analysis confirms that public-sector research has a significant impact on drug development, with public-sector patents leading to the most innovative drugs. Public science is essential in supporting U.S. industry and technology advancement, with a majority of papers cited in patents coming from academic and public facilities. Research by Professors Cohen, Nelson, and Walsh shows that public research significantly influences industrial R&D across various industries. The biomedical sector heavily relies on public science, with 79% of drug patents citing public research results. Government-funded research plays a crucial role in drug development, contributing to the discovery of basic phenomena, development of new techniques, and clinical applications of drugs. Federal funding plays a crucial role in pharmaceutical product innovation by contributing to the discovery of basic phenomena, development of new techniques, and clinical applications of drugs. Research has shown that publicly funded basic research is a significant factor in the development of top-selling pharmaceuticals. Multiple sources and parties are involved in drug development, making it difficult to pinpoint the exact government contribution to a new drug. The National Institutes of Health (NIH) conducted a detailed analysis of top-selling drugs in 1994 and 1995, finding that research for drug development can be disease-targeted or aimed at basic mechanisms. NIH's technologies were used in the development of four out of 47 FDA-approved drugs with sales over $500 million a year. NIH funded technologies were used in the development of four pharmaceuticals: Epogen\u00ae and Procrit\u00ae based on patented process technology from Columbia University, Neupogen\u00ae from Memorial Sloan-Kettering Cancer Center, and Taxol\u00ae from Florida State University. NIH received royalties from Bristol Myers Squibb for the use of NIH-funded technologies. The 2003 study by GAO found that government financial support of extramural research and development led to limited direct contributions to final therapeutic products. The government does not retain ownership of inventions made by contractors, making it difficult to track federal contributions. The potential life-saving quality of products from this type of R&D goes beyond economic considerations. Advances in biotechnology and pharmaceuticals can lead to economic growth through improved productivity from a healthier population. Federal support for health-related R&D is significant, amounting to 21.5% of the total federal R&D budget. Some suggest that the government should have a more direct return on investment in pharmaceutical prices. Government involvement in pharmaceutical pricing is a topic of debate, with some suggesting that the government should recoup its investment in federally supported R&D from firms after profits are made. The government provides funding for research and grants patent protection to firms, along with financial, regulatory, and tax advantages through legislation like the Hatch-Waxman Act. Critics argue that the drug industry has benefited from a lack of close scrutiny and a lenient regulatory environment. The Boston Globe's investigation found that pharmaceutical companies benefit from government-funded research, leading to high drug prices. Government funding of basic research is seen as a public good, with firms reaping significant profits from drugs developed with public money. The public investment in research replaces some patent incentives for drug development, challenging the necessity of patent protection. High drug prices are not solely due to R&D costs, as federal funding and fast-track approvals play a significant role. Proponents of recoupment and federal cost controls argue that public investment in research should entitle the public to a return on its investment. They believe that prices of pharmaceuticals should reflect the public contribution to the products. Critics, however, oppose policies to recoup federal research support or government involvement in pricing decisions. Critics argue that advocates of recouping federal research support misunderstand the nature of NIH's role in research and pharmaceutical development. Federal support for basic research is crucial for innovation, with returns often long-term and not always marketable. Studies show a high rate of return on government-funded biomedical research, potentially reaching 30% annually. The National Institutes of Health funds basic research aimed at understanding biological mechanisms for new ideas, which industry may use for product development. This research supports the discovery process in pharmaceutical innovation and precedes chemical synthesis. The National Institutes of Health funds basic research that has a substantial impact on pharmaceutical R&D by exploring fundamental biological mechanisms. This research can lead to early-stage findings and provide clues for medical advancements in diseases with limited treatment options. Pharmaceutical companies primarily focus on applied research for developing new drugs, spending more on R&D than the NIH. The National Institutes of Health funds basic research that impacts pharmaceutical R&D by exploring biological mechanisms, leading to medical advancements. Critics argue the federal role in drug development is overstated due to skewed results from citations. A study by NIH shows public and private sector research are complementary, with government involvement in preclinical and clinical development of drugs for serious diseases. The NIH plays a significant role in drug development, particularly for diseases where there is a public health benefit. The involvement of NIH in discovering compounds in the public domain, not initially of interest to the pharmaceutical industry due to limited patent claims, is crucial. Critics argue against changes in intellectual property ownership of federally funded R&D results, emphasizing the importance of patents in the research-intensive pharmaceutical and biotechnology industries. The high costs of drug innovation and low costs of imitation make intellectual property vital for promoting innovation. The pharmaceutical industry invests significantly in R&D, with biotechnology companies relying on intellectual property for funding. Patents are crucial for raising equity capital and promoting innovation in the industry. Eliminating incentives related to technology transfer and patent ownership would hinder innovation, according to experts. Experts warn that weakening patent protection and government violation of patents could reduce innovation in the pharmaceutical industry. Faster research and development processes are essential for competition, and cutting off financial rewards may hinder drug supply. Imposing drug price controls or limiting industry returns could also impact innovation and investment in the sector. Experts caution that pharmaceutical price regulation and government violation of patents may hinder innovation in the industry. Research shows that companies without control over their investments are less likely to engage in related R&D. The Bayh-Dole Act incentivizes cooperative work and commercial application by providing ownership of patents from federally funded R&D to universities, nonprofit institutions, and small businesses. The Bayh-Dole Act incentivizes cooperative work and commercial application by providing ownership of patents from federally funded R&D to universities, nonprofit institutions, and small businesses. Royalties from intellectual property rights support further research and provide a return on financial contributions. Congress rejected the idea of recoupment as an unnecessary burden, opting instead for increased revenues through taxes on profits, job creation, and economic growth. The Bayh-Dole Act allows universities, nonprofit institutions, and small businesses to own patents from federally funded R&D, leading to increased tax revenues and economic benefits. Critics argue that patenting fundamental research hinders biomedical innovation by focusing on proprietary claims rather than promoting scientific advancement. Ownership of research tools, such as inventions leading to commercial products and fundamental advances, may result in delayed innovation, litigation, and hinder research by others. Broad claims on early discoveries can impede scientific progress by limiting independent minds at work. Concerns about seeking early intellectual property protection were raised by Harold Varmus, president of Memorial Sloan-Kettering, as it can have detrimental effects on science. The Bayh-Dole Act and scientific advances have fueled the biotechnology industry, but changes may not always benefit science. Yale President Richard Levin believes that privatization of research tools is due to patent law, not the Bayh-Dole Act. Efforts have been made to promote widespread availability of these tools despite court decisions allowing their patenting. Efforts have been made to promote the widespread availability of research tools in the biotechnology industry. The National Institutes of Health has developed guidelines for sharing research tools among non-profit organizations with minimal terms and impediments. This approach is now a requirement in NIH grants and reflects changes to the Bayh-Dole Act to achieve research results without hindering future discoveries. The U.S. Patent and Trademark Office has also made changes to guidelines for determining the patentability of biotechnology. The U.S. Patent and Trademark Office has made changes in guidelines for determining the patentability of biotechnology discoveries. A study found that despite more patents in biomedical research, there is little evidence of research being curtailed due to intellectual property issues. Scientists can continue research through various means like licensing, inventing around patents, and using technology without a license. Private sector owners of patents allow infringement in academia to increase the value of patented technology, while the government retains rights under the Bayh-Dole Act to protect the public interest. The government retains rights under the Bayh-Dole Act to protect the public interest, including a \"royalty free license\" for subject inventions. A 2003 GAO report clarified that this license does not allow the government to purchase products at a discounted price that incorporate federally funded inventions, unless produced under the government's license. The government retains rights under the Bayh-Dole Act for subject inventions, including a \"royalty free license.\" Federal officials indicated that procurement costs were best reduced by using the Federal Supply Schedule and national contracts. Government licenses are primarily used for research in the biomedical area, and tracking the government's interest in patents from federally funded research is a related issue. Grantees are required to report annually on the utilization of any invention arising from federally funded R&D. However, federal contractors and grantees were not meeting the reporting requirements associated with the Bayh-Dole Act, making it difficult to identify and assess inventions. In a 1999 study, GAO found federal contractors and grantees were not meeting reporting requirements of the Bayh-Dole Act, hindering identification of government-retained licenses. In a 2002 update, GAO noted agencies had improved compliance with new monitoring systems. NIH created iEdison in 1995 to track inventions under the Act. New reporting requirements were implemented in 2002, including disclosing FDA-approved products using subject inventions. The U.S. system has impacted pharmaceutical and biotechnology industries. The U.S. system of research, development, and commercialization has significantly impacted the pharmaceutical and biotechnology industries. American pharmaceutical firms lead in new drug discoveries and maintain a competitive edge in international markets. U.S. investment in health-related R&D exceeds all other countries, with incentives for innovation contributing to substantial research and development. In 2010, the biopharmaceutical industry in the United States spent between $67.4 billion and $68.0 billion on research and development. The Pharmaceutical Research and Manufacturers of America (PhRMA) and U.S. biotechnology companies invested billions in research and development, creating new products and processes for the international marketplace. The industry employs around 291,000 individuals in skilled jobs. Some observers question the unintended consequences of current innovation policies. The legislative approach promotes private sector use of federally funded research results through cooperative activities among government, industry, and academia. Incentives for commercializing government-supported R&D aim to balance public interest in new products with concerns over accountability. Critics argue that industry benefits from free access to R&D, patent protection, and regulatory advantages, questioning the need for additional technology development incentives. The debate surrounds government-supported R&D benefits to industry, with some advocating for a more direct financial return for federal investment, while others highlight the innovation and public health benefits generated by the collaborative environment. The potential for changes in government-industry-university cooperation remains uncertain."
}